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ABSTRACT
Novel adjuvants are needed to increase the efficacy of vaccine formulations and 
immune therapies for cancer and chronic infections. In particular, adjuvants that 
promote a strong type I IFN response are required, since this cytokine is crucial for 
the development of efficient anti-tumoral and anti-viral immunity. Nucleic acid band 
2 (NAB2) is a double-stranded RNA molecule isolated from yeast and identified as an 
agonist of the pattern-recognition receptors TLR3 and MDA-5. We compared the ability 
of NAB2 to activate innate immunity with that of poly(I:C), a well-characterized TLR3 
and MDA-5 agonist known for the induction of type I IFN. NAB2 promoted stronger 
IFN-α production and induced a higher activation state of both murine and human 
innate immune cells compared to poly(I:C). This correlated with a stronger activation 
of the signalling pathway downstream of MDA-5, and IFN-α induction was dependent 
on MDA-5. Upon injection, NAB2 induced higher levels of serum IFN-α in mice than 
poly(I:C). These results suggest that NAB2 has the potential to become an efficient 
adjuvant for the induction of type-I IFN responses in therapeutic immunization 
against cancer or infections.
INTRODUCTION
A major focus of current research is the development 
of novel and more effective immune stimulants that can be 
used as adjuvants, in order to increase vaccine efficacy and 
safety [1]. Moreover, considering the rising importance 
of immunotherapy for cancer treatment, there is a need 
for effective immune modulators that can improve 
current anti-cancer immunotherapeutic approaches. A 
class of molecules that were shown to be highly efficient 
adjuvants are the pathogen-associated molecular patterns 
(PAMPs) [2]. PAMPs comprise molecular structures, such 
as specific lipids moieties, nucleic acid structures and 
lipoproteins, that are highly conserved across a wide range 
of microorganisms, and whose recognition by immune 
cells can play a critical role in the early detection of 
invading pathogens. Indeed, PAMPs can trigger a specific 
group of innate immune sensors, called pattern-recognition 
receptors (PRRs), which, upon stimulation, promote 
the initiation of the innate immune response and the 
development and coordination of the subsequent adaptive 
immune response [3]. Different types of PRRs exist, 
depending on their subcellular localization and the target 
they recognize. Nucleic acid-sensing PRRs are triggered 
by specific DNA and RNA structures, and are of particular 
importance for the detection of viral infections [4]. Indeed, 
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a consequence of nucleic acid sensing by immune cells is 
the production of key anti-viral cytokines such as type I 
IFNs, mainly by conventional and plasmacytoid dendritic 
cells (cDCs and pDCs) and macrophages [5]. Importantly, 
type I IFNs are central linkers of the innate and adaptive 
immune response, and are known to mediate prominent 
anti-tumoral effects [6]. Thus, the stimulation of nucleic 
acid sensors, through synthetic molecules or naturally 
occurring nucleic acids, is of a special interest for cancer 
therapy. 
Polyriboinosinic–polycytidylic acid (poly(I:C)) is a 
synthetic double-stranded RNA (dsRNA) that is an agonist 
for the nucleic acid sensors Toll-like receptor 3 (TLR3) [7] 
in the endosome and Melanoma Differentiation-Associated 
protein 5 (MDA-5) [8], a cytosolic receptor belonging to 
the RIG-I-like receptor (RLR) family. Poly(I:C) is currently 
the most consistently active variant of polynucleotide 
products that, signalling through TLR3 and MDA-5, is 
able to induce a strong IFN activity [9]. Preclinical tests 
have shown that poly(I:C), included as adjuvant in cancer 
vaccines [10] but also as a stand-alone treatment [11], is 
able to promote an efficient anti-tumoral immune response, 
activating DCs, NKs and T cells [12, 13]. However, the use 
of poly(I:C) or poly(I:C) analogues in clinical settings is 
still limited, mainly due to its unfavourable toxicity profile 
[14, 15]. Furthermore, the high variability of the poly(I:C) 
effects that is associated with the use of different product 
batches, as often observed even in preclinical tests, is a 
critical downside of this PRR agonist.
Recently, a novel TLR3 and MDA-5 agonist was 
identified and isolated from a microsomal Saccharomyces 
cerevisiae yeast extract. This molecule turned out to be 
a 4.6-kb dsRNA molecule with a sequence identical to a 
yeast dsRNA virus belonging to the Totoviridiae family, 
and it was termed nucleic acid band 2 (NAB2) [16]. NAB2 
was shown to induce the secretion of pro-inflammatory 
cytokines and type I IFNs in human monocyte-derived 
DCs, signalling through TLR3 and MDA-5. Moreover, 
NAB2 injection augmented the efficacy of a prophylactic 
anti-cancer vaccine in a transplantable tumor mouse 
model, increasing tumor rejection rate and survival [16]. 
The aim of this work was to compare the efficacy 
of NAB2 and poly(I:C) as innate immune stimulants: 
we set out to assess whether NAB2 could represent 
a more reliable adjuvant, able to circumvent the lack 
of reproducibility typically associated with different 
poly(I:C) batches and to consistently induce a strong 
cytokine response. We report here that NAB2, through an 
enhanced activation of MDA-5 downstream signalling, 
promoted a stronger IFN-α production by murine and 
human innate immune cells in vitro, and a significant 
increase in IFN-α serum levels in vivo, than poly(I:C). 
We propose that NAB2 represents a valid alternative to 
poly(I:C) as nucleic acid-sensor agonist, with a potentially 
improved efficacy in the immune-based treatments of 
cancer and as vaccine adjuvant. 
RESULTS
NAB2 induces stronger type I IFN responses 
than the same doses of poly(I:C) 
To compare the cytokine-producing ability of 
poly(I:C) and NAB2, we first assessed the effect of the 
two agonists on murine bone marrow-derived dendritic 
cells (BMDC). To monitor RLR and TLR activity upon 
stimulation, we measured IFN-α and IL-6 production, 
respectively, because they represent the signature 
cytokines for each of these pathways [17]. IFN-α 
production was clearly increased in a dose-dependent 
manner in cells treated with NAB2 and the transfection 
reagent lipofectamine, whereas we did not observe any 
difference in IL-6 production in NAB2 and poly(I:C)-
treated cells (Figure 1A). Furthermore, CXCL-10, that 
is known to be induced by type I and type II IFNs [18], 
was also increased upon NAB2 stimulation compared 
to poly(I:C). Without lipofectamine we observed only 
marginal cytokine production upon both NAB2 and 
poly(I:C) stimulation. We did not observe a detectable IL-
10 production (data not shown), and only a marginal IL-
12p40 production (Figure 1A) with NAB2 and poly(I:C). 
We observed a similar effect using freshly isolated murine 
bone marrow cells and splenocytes: the stimulation of 
both these primary cell populations with NAB2 induced 
a higher IFN-α production and only a marginal amount of 
IL-6, compared to poly(I:C) (Figure 1B). 
To characterize the phenotype of dendritic cells 
stimulated with NAB2 and poly(I:C), we evaluated the 
surface expression of different activation markers and co-
stimulatory molecules on BMDC (Figure 1C upper panels) 
and splenic DC (Figure 1C lower panels). In line with the 
cytokine profile of stimulated BMDC, we observed a 
higher MHC class I and PD-L1 expression upon NAB2-
mediated stimulation compared to poly(I:C) (Figure 1C), 
both in BMDC and splenic DC, suggesting an enhanced 
DC maturation. In contrast, NAB2 induced a similar 
surface expression of the co-stimulatory molecules CD80, 
CD86 and CD40 in BMDC, and only splenic DC showed 
an increased CD86 expression upon NAB2 stimulation. 
In summary, we show that NAB2 stimulation promotes a 
more pronounced type I IFN response in different types of 
murine immune cells, and a more marked activation state 
of BMDC, compared to poly(I:C).
NAB2-activated BMDC induce antigen-specific 
T-cell production of effector cytokines
 To determine the capacity of NAB2-stimulated 
cells to induce an antigen-specific T-cell response, and 
considering the increased MHC-I expression upon NAB2 
stimulation, we isolated CD8+ T cells from OT-I mice and 
co-cultured them with OVA-pulsed BMDC, which were 
pre-stimulated with NAB2 or poly(I:C). 3 days later, we 
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measured the amount of IL-2 and IFN-γ in the co-culture 
supernatant. BMDC that were incubated with NAB2 and 
lipofectamine induced the highest cytokine production, 
also in comparison to poly(I:C)-stimulated cells (Figure 2). 
Of note, in the absence of lipofectamine, NAB2 induced 
only a marginal IL-2 and IFN-γ production, similarly 
Figure 1: NAB2 enhances type I IFN response in murine immune cells. (A) Cytokine levels in the supernatant of BMDC, 
stimulated for 24 h with 0.5, 2 and 5 µg/ml of NAB2 or poly(I:C), with and without lipofectamine, measured by ELISA. For IL-6, CXCL10 
and IL-12p40 plots, results of stimulation with 2 µg/ml NAB2 or poly(I:C) are represented. Mean ± SEM of triplicates are shown. Data are 
representative of four independent experiments. Significance was measured by two-way ANOVA with Bonferroni post-test correction or 
Student t-test, respectively for IFN-α and for IL-6, CXCL10 and IL-12p40. (B) Cytokine levels in the supernatant of freshly isolated bone 
marrow cells (BM) and splenocytes (SP), stimulated for 24 h with 2 µg/ml of the indicated agonists. Mean ± SEM of triplicates are shown. 
Data are representative of at least 2 independent experiments. (C) Surface expression of activation markers on BMDC (upper panels) and 
splenic DC (SP) upon 24 h stimulation with 2 µg/ml of the indicated agonists, measured by flow cytometry. Geometric mean fluorescence 
intensity (gMFI) fold increase compared to unstimulated cells is plotted. Bar plots represent pooled data of at least three independent 
experiments performed in triplicate. Mean ± SEM are shown. Significance was measured by Student t-test. *p < 0.05, **p < 0.01. n.d., 
cytokine levels below detection limit.
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to poly(I:C)-stimulated BMDC. In the absence of the 
antigen, we did not detect cytokine production in any of 
the conditions tested, showing the specificity of the T-cell 
response. Thus, NAB2-stimulated dendritic cells are able 
to activate T cells in an antigen-specific manner, and to a 
greater extent than poly(I:C). 
NAB2 increases IRF3 activation compared to 
poly(I:C) 
To investigate the mechanism causing the enhanced 
IFN-α response upon NAB2 stimulation, we performed 
immunoblot analysis on the cell lysate of murine BMDC 
stimulated for 2 h with NAB2 or poly(I:C). As both 
agonists were reported to signal through TLR3 and MDA5 
pathways [7, 8, 16], we analysed the activation of the 
main transcription factors downstream to these receptors. 
The two agonists induced an equal phosphorylation of the 
p65 subunit of the transcription factor NF-κB, which is 
mainly responsible for the expression of pro-inflammatory 
cytokines, such as IL-6, following TLRs stimulation [19]. 
In contrast, NAB2 increased the phosphorylation of the 
transcription factor IRF3, which regulates the expression 
of type I IFNs following RLR and TLR3 stimulation 
[20] (Figure 3A). NAB2 and poly(I:C) did not affect 
the total p65 or IRF3 amount. MDA-5 was below the 
detection limit in all conditions (data not shown). Thus, the 
phosphorylation patterns of IRF3 and p65 correlate with the 
cytokine response observed following NAB2 and poly(I:C) 
stimulation. Bone marrow cells from mice deficient for 
MDA-5 produced no IFN-α following NAB2 stimulation, 
demonstrating that the induction of this cytokine is entirely 
MDA-5 dependent (Figure 3B). Thus, NAB2 promotes an 
enhanced type I IFN response in BMDCs by modulating 
the MDA-5 downstream signalling pathway, and in 
particular by inducing a stronger IRF3 activation.
NAB2 increases type I IFN responses in vivo
To examine whether the differential response 
induced by NAB2 and poly(I:C) was detectable in vivo, 
we injected mice with the two PRR agonists, and 4 h later 
we measured the cytokine levels in the serum. Again, 
while we did not detect a statistical significant difference 
in IL-6 production (data not shown), NAB2 induced a 
markedly increased IFN-α serum expression, compared 
to poly(I:C) (Figure 4). Of note, we did not observe any 
signs of toxicity following NAB2 injections. Thus, NAB2 
is more efficient than poly(I:C) in promoting a type I IFN 
response, in vitro as well as in vivo. 
NAB2 augments the IFN I response of human 
monocyte-derived macrophages compared to 
poly(I:C)
To assess whether our observations in the mouse 
model were valid also in human cells, we stimulated 
with the two PRRs agonists human monocyte-derived 
macrophages generated according to Mia et al. [21]. We 
tested the effect of NAB2 on macrophages because in 
our previous published [22] and unpublished work, we 
observed that the anti-tumoral effect of PRR stimulation 
combined with a prophylactic vaccine was dependent 
on the activation status and cytokine profile of tumor-
infiltrating macrophages. A combination of M-CSF, 
IL-4/IL-10/TGF-β yielded a phenotype of adherent 
CD206+CD163+ macrophages with downregulated CD86 
expression. We analysed the cell activation state and IFN-α 
production following stimulation. Similarly to the mouse 
system, the stimulation with NAB2 induced a marked 
increase of IFN-α production (Figure 5, left) and CD86 
expression on human macrophages (Figure 5, right). In 
contrast, poly(I:C) did not cause any detectable effect. We 
Figure 2: NAB2-stimulated BMDC activate CD8+ OT-1 T cells to produce IL2 and IFNγ. Levels of IL2 and IFNγ in 
supernatant of CD8+ OT-1 T cells after 3 days of co-culture with OVA peptide-loaded or unloaded BMDC stimulated for 24 h with 2 µg/
ml of NAB2 or poly(I:C), with and without Lipofectamine (Lipo), or unstimulated (NS). Cytokines were quantified by ELISA. Plots show 
cumulative data of two independent experiments. Mean ± SEM of triplicates are shown. Statistical analysis was performed with Student 
t-test. **p < 0.01, n.d., not determined, cytokine levels below detection limit.
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did not detect IFN-α production or CD86 up-regulation 
upon stimulation in the absence of the transfection reagent. 
Taken together, our observations suggest that NAB2 
induces a consistent and more potent type I IFN response 
compared to poly(I:C) both in human cells and in mice.  
DISCUSSION
Vaccine formulations that exploit the nucleic 
acid-sensing mechanisms of immune cells can be used 
to maximize the response against cancer and chronic 
Figure 3: NAB2 increases IRF3 but not NF-κB signalling in murine BMDC. (A) Immunoblot analysis of p65 and IRF3 
phosphorylation in lysate of BMDC. Cells were stimulated for 2 h with poly(I:C) or NAB2, both complexed with lipofectamine, or not 
stimulated (NS). Individual blots are depicted by rectangles. Signal intensity is expressed as fold increase referred to unstimulated samples, 
normalized to β-actin.  Blots are representative of two independent experiments. (B) IFNα levels in the supernatant of bone marrow cells 
from WT and MDA-/- mice stimulated for 18 h with NAB2 or poly(I:C) using Lipofectamine 2000® (Lipo) or Mirus TransIT LT1® (Mirus 
LT1) as transfection reagent. Mean ± SEM of triplicates are shown. Poly (A) was used as negative control. 3P-RNA and DNA were used 
as positive controls. All the stimulants were used to a final concentration of 200 ng/well.  Statistical analysis was performed with Student 
t-test. *p < 0.05, n.d., not determined, cytokine levels below detection limit.
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infections, mainly for their capability to induce a 
potent type I IFN response. Indeed, type I IFNs are 
crucial mediators of the anti-tumoral immune response, 
promoting DC maturation, antigen cross-presentation and 
in turn activation of cytotoxic T lymphocytes, NK cells 
activation and polarization of Th1 cells [23]. Moreover, 
the ability of type I IFNs to prime spontaneous anti-
tumoral T-cell responses [24] makes these pleiotropic 
cytokines, and the mechanisms that drive their production 
highly attractive targets of cancer immunotherapeutic 
approaches [25]. 
The synthetic dsRNA poly(I:C) is currently 
considered the most potent inducer of type I IFNs among 
all TLRs agonists [26]. However, poly(I:C) limitations, 
such as batch-dependent variability and high toxicity, 
hampered its use in clinical settings and highlight the need 
for new and more efficient TLR3 and MDA-5 targeting 
adjuvants. In this work we show that NAB2, a yeast-
derived dsRNA molecule that also signals through TLR3 
and MDA-5, is able to induce a stronger IFN-α production 
and innate immune cell activation compared to poly(I:C), 
both in the mouse and human systems. Moreover, since the 
production process of NAB2 is based on the isolation of 
viral genomic RNA, the length of the molecule is constant 
in different batches, assuring highly reproducible results 
(Supplementery Figure 4). NAB2 also induces a higher 
CXCL10 production, in spite of a similar IL-6 expression. 
While the comparable IL-6 expression may be due to 
the similar capacity of NAB2 and poly(I:C) to activate 
the NF-κB pathway, the different CXCL10 production 
suggests that its expression is driven by NAB2 mainly 
through IRF3 activation. However, it is also possible that 
CXCL10 production is induced in a paracrine manner by 
type I IFNs [27]. Considering a) that CXCL10 expression 
is associated with Th1 immune responses and b) the 
role of CXCL10 in attracting activated T cells [28, 29], 
NAB2 appears as a promising adjuvant to promote cell-
mediated immunity. Indeed, we additionally demonstrate 
the potentiated antigen-presenting function of NAB2-
stimulated BMDC in vitro: MHC-I surface expression 
increases upon NAB2 stimulation, and BMDC gain the 
capacity to activate CD8+ T cells in an antigen-specific 
manner to produce IL-2 and IFN-γ. Our data indicate that 
NAB2 represents a novel immune stimulant with a high 
therapeutic potential, especially in the context of cancer 
immunotherapy, although further studies are needed to test 
the adjuvant potential of NAB2 in vivo.
Of note, we observed that NAB2 promoted a 
stronger IFN-α expression compared to poly(I:C) only 
when the two agonists were complexed with lipofectamine, 
Figure 4: NAB2 increases IFN-α serum levels in vivo. IFN-α levels in the serum of mice treated with the NAB2 or poly(I:C). Mice 
were injected i.p. with 50 µg/mouse of poly(I:C) or NAB2 plus Lipofectamine. Cytokines in the serum were measured by ELISA 4 h after 
the injection. Each dot represents one mouse (n = 4). One of two independents experiments is shown. Significance was measured by Student 
t-test. **p < 0.01.
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a transfection reagent which allows their direct entry in 
the cytoplasm. On the contrary, the two PRRs induced a 
similar and only marginal amount of IFN-α when applied 
without carrier. It was previously shown that, when 
poly(I:C) and NAB2 are complexed with lipofectamine, 
the main receptor that is triggered is the RLR MDA-5 [16, 
17]. We could confirm this here using immune cells from 
MDA5-deficient mice. In line with this, delivery of NAB2 
to the cytoplasm by using the alternative carrier TransIT®-
LT2 (Mirus) produced similar results in terms of IFN-α 
production by human PBMCs (Supplementery Figure 3). 
DOTAP, which delivers nucleic acids to the endosome, 
was less effective. Altogether these observations suggest 
that NAB2 is a more efficient MDA-5 agonist than 
poly(I:C), while they induce a similar TLR3-dependent 
response. In line with this, NAB2 might exert a different 
function compared to poly(I:C) depending on the cell type, 
as a consequence of different cellular distribution of the 
MDA-5 and TLR3 receptors [9]. For example, compared 
to poly(I:C), NAB2 might have a major impact on NK 
cells activation, since this cell type crucially relies on 
MDA-5 for nucleic acid sensing, whereas TLR3 plays 
only a marginal function [30]. 
The mechanism by which NAB2-stimulation 
improves the MDA-5-dependent response remains to be 
defined. Basal expression of MDA-5 is usually low, and 
it can be induced by cytokines such as IFN-β and TNF-α 
[31]. However, it is unlikely that the increased MDA-5 
signalling induced by NAB2 is due to an up-regulation 
of the receptor expression, since we could not detect a 
significant MDA-5 expression in any of the conditions 
tested, even upon stimulation by NAB2 or poly(I:C). 
IRF3 is the major transcription factor that regulates type 
I IFN responses upon nucleic acid sensing in innate 
immune cells [19]. We observed an increased IRF3 
phosphorylation upon NAB2 stimulation, but a similar 
NF-κB activation induced by the two agonists. NAB2 
might thus impact the MDA-5 downstream signalling at 
the level where the pathways involving IRFs or NF-κB 
diverge. Upon dsRNA recognition, MDA-5 interacts with 
IPS-1, or Mitochondrial antiviral-signaling adaptor protein 
(MAVS) [32], which is considered the point of divergence 
of the two pathways. Following interaction with MDA-
5, IPS-1 may activate the TBK1/IKKε kinases, which in 
turn phosphorylate IRF3 [33], or alternatively activate 
IKK, and finally NF-κB, in a signalling cascade involving 
FADD-RIP1 and caspase-8/10 [34]. Further experiments 
are needed to fully elucidate the signalling events leading 
to IRF3 phosphorylation. 
On the structural level, MDA-5 recognizes long 
dsRNA molecules by cooperatively assembling into 
helical filaments [35]. The length and lifetime of MDA-5 
filaments is determined also by the length of the dsRNA 
molecule, and this is a crucial factor in determining 
the MDA-5 signalling output [36]. Thus, a possible 
explanation of the improved MDA-5-dependent response 
upon NAB2 stimulation is the increased length of the 
NAB2 molecule, compared to poly(I:C).
Different-size poly(I:C)s are commercially 
available, usually referred to as high (HMW) or low 
molecular weight (LMW) poly(I:C)s, with a respective 
average size of 1.5–8 kb and 0.2–1 kb. Both poly(I:C) 
Figure 5: NAB2 enhances IFN-α production and activation of human monocyte-derived macrophages. IFN- α levels 
in the supernatant of human monocyte-derived macrophages (left) and CD86 surface expression (right) on macrophages treated with the 
indicated agonists for 16 h. IFN-α was measured by Luminex analysis and the CD86 surface expression was measured by flow cytometry. 
CD86 expression is expressed as geometric mean fluorescence intensity (gMFI). Each dot represents one independent donor (n = 3). For 
each donor, the mean of two independent experiments is shown. Significance was measured by Student t-test. *p < 0.05.
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formats are able to signal through TLR3 and MDA-5, 
but there are contrasting results concerning their relative 
efficacy [37, 38]. In this work we compare NAB2 with 
LMW poly(I:C), because, from previous observations of 
our group, LMW poly(I:C) produces more reproducible 
results compared to HMW poly(I:C), with regard to 
its innate immune cell-stimulant activity ([17] and 
unpublished results). Moreover, we previously showed 
how LMW poly(I:C) has a strong anti-tumoral effect in 
an active immunotherapy approach [39]; taken together, 
we thus consider LMW poly(I:C) a proper and effective 
control for testing NAB2 immune stimulant activity in 
pre-clinical experiments. However, it would be of interest 
to compare NAB2 immune stimulatory activity with other 
poly(I:C) formulations.
In conclusion, considering the strong type I 
IFN response induced, NAB2 has the potential to be a 
more efficient adjuvant than poly(I:C) for therapeutic 
immunization against cancer or infections. Our work 
provides the rationale to compare the efficiency of NAB2 
and poly(I:C) in a therapeutic setting, such as the anti-
tumoral effect of their administration in mouse tumor 
models. However, it is important to keep in mind that 
the most prominent adverse effect of the use of poly(I:C) 
or poly(I:C)-derived compounds in clinical settings are 
attributed to the induction of systemic inflammatory 
responses. Although we observed no signs of toxicity in 
mice receiving high doses of NAB2, further studies are 
needed to carefully evaluate the potential side effects of 
NAB2-mediated immune stimulation, and to test the use 
of more targeted delivery strategies [40, 41].
MATERIALS AND METHODS
Human monocyte purification and immune 
stimulation
Human monocytes were isolated and purified 
from peripheral blood mononuclear cells (PBMCs) of 
buffy coats obtained from healthy donors (Etablissement 
Français du Sang, Strasbourg) using Ficoll-Paque 
PLUS (GE Healthcare) according to the manufacturer’s 
instructions. After isolation from PBMCs either by 
positive CD14+ selection or by negative selection 
using monocyte isolation kit II (Miltenyi, Biotec), 
4 × 105 monocytes were cultured on 48-well plates in 
500 µl Macrophage Base Medium DXF (Promocell) 
supplemented with 50 ng/ml M-CSF (Miltenyi Biotec). 
Medium was changed at day 3 and day 7. At day 7, 
CD16hiCD68+CD11b+ M0 macrophages were polarized 
towards a M2 phenotype adding IL-4, IL-10 and TGF-
beta (Miltenyi Biotec) to a concentration of 20 ng/ml. Two 
days later, CD163+ CD206+ M2 macrophages were treated 
with NAB2 or poly(I:C) (LMW (tlrl-picw, Invivogen)) 
mixed or not with Lipofectin reagent (Invitrogen) in 
Opti MEM medium (Gibco, Thermo Fisher). 50 µl of 
the respective mix were added per well for 16 h. For 
testing different transfection reagents, freshly isolated 
PBMCs were stimulated with NAB2 transfected with 
Lipofectamine (Invitrogen, Thermo Fisher Scientific), 
DOTAP (Carl Roth) and TransIT®-LT2 (Mirus Bio LLT) 
diluted in Opti MEM (Gibco, Thermo Fisher Scientific). 
Supernatants were collected after 24 h for cytokine 
detection. 
Mice and treatments
Wild-type C57BL/6J mice were purchased from 
Janvier labs (Le Genest-St-Isle, France). MDA-5-
deficient mice (C57BL/6 background) and WT controls 
were from the University of Bonn. Mice were maintained 
in specific-pathogen free conditions and used between 
6-14 weeks of age. In the indicated experiments, mice 
were injected i.p. with 50 µg/mouse of poly(I:C) low 
molecular weight (Invivogen, Toulouse, France),  or 50 µg/
mouse NAB2 (Transgene S.A., Illkirch-Graffenstaden, 
France), complexed with Lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA). 4 h after the injection, mice 
were euthanized, and blood was collected by cardiac 
puncture, for the analysis of serum cytokines. All animal 
experimentation procedures were performed according to 
the Swiss or German federal legislation.
Murine cell culture and immune stimulation
Primary cells from bone marrow and spleen were 
obtained as described in [42]. To prepare conventional 
BMDCs, bone marrow cells were cultured in RPMI 1640 
medium, 50 U/mL penicillin, 50 µg/mL streptomycin, 
2 mmol/l L-glutamine (all from PAA laboratories, 
Pasching, Austria), 10% (v/v) fetal calf serum (Life 
Technologies, Grand Island, NY), supplemented with 
20 ng/ml GM-CSF (PeproTech, Rocky Hill, NJ). On day 
6, loosely adherent cells and cells in suspension were 
harvested and used for the indicated experiments. For 
cell stimulations, a total of 2 × 105 BMDCs or 2–4 × 
105 primary bone marrow cells and splenocytes per well 
were seeded in 96-well plates. Stimulation of the cells 
was performed in complete medium, with the agonists at 
the concentrations indicated in the figure legends for 18-
24 h. The same 2 h stimulation protocol was performed 
for flow cytometry analysis, cytokine production, and for 
the analysis of the activation of intracellular signalling 
pathways. Low molecular weight poly(I:C) and R848 
were purchased respectively from Invi vogen and Enzo 
Life Sciences (New York, NY). NAB2 was provided by 
Transgene S.A. Poly(I:C), NAB2, 3P-RNA and pDNA 
transfections were performed with Lipofectamine (Life 
Technologies), TransIT-LT1 or LT2 (Mirus Bio LLT) 
according to manufacturers’ specifications. 
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Flow cytometry and ELISA
For flow cytometry analysis, cells were incubated 
for 10 min with Fc receptor-blocking antibody (TruStain 
fcX, Biolegend, San Diego, CA) and stained with 
fluorescently labeled antibodies. Anti-mouse CD11b 
(M1/70), CD11c (N418), MHC-II (M5/114.15.2), CD80 
(16-10A1) and CD86 (GL-1) were used. Pacific blue-
coupled Armenian hamster IgG antibody (HTK888), 
phycoerythrin-coupled rat IgG2a,κ (RTK2758) and 
APC-Cy7-coupled rat IgG2b,κ (RTK4530), were used as 
isotype controls. All these antibodies were purchased from 
Biolegend (San Diego, CA). Anti-mouse CD40 (1C10), 
PDL1 (MIH5), MHCI (AF6-885.5.3) were purchased 
from eBioscience (Thermo Fisher Scientific). All cell 
acquisitions were recorded using the MACSQuant system 
from Miltenyi Biotec (Bergisch Gladbach, Germany) or 
the NovoCyte Flow Cytometer (ACEA Biosciences). Data 
were analyzed using FlowJo vX.0.7 software (Tree Stat, 
Inc., Ashland, USA). For the flow cytometry analysis of 
human monocytes, cells were incubated for 20 min with 
human FcR Blocking Reagent (Miltenyi Biotec) and APC-
labeled anti-CD86 (clone FM95, Miltenyi Biotec). Dead 
cells were labeled by automatic propidium iodide staining 
before cell acquisition recorded using MACSQuant 
cytometer (Miltenyi). Data were analyzed using Kaluza 
software (Beckman Coulter). Cytokine levels in the 
supernatant of stimulated cells and serum of treated mice 
were quantified by sandwich ELISA, following the kit 
protocols (BD Biosciences and BioLegend, San Diego, 
CA). For human monocytes, the supernatant of stimulated 
cells was taken and IFN-alpha levels were measured 
(Human IFN-alpha Simplex, ProcartaPlex, eBiosciences) 
on a MAGPIX device (Luminex XMAP Technologies). 
Immunoblot analysis
BMDCs (4 × 106/well) were seeded in 24-well 
plates and stimulated in serum-free Opti-MEM (Life 
Technologies, Invitrogen). Immunoblot analysis was then 
performed as described in [17]. The following primary 
antibodies were used: anti–β-actin (8H10D10), anti–
phospho-p65 (Ser536, 93H1), anti-p65 (L8F6 or D14E12), 
anti–phospho-IRF3 (4D4G), anti-IRF3 (D83B9), and anti–
MDA-5 (D74E4). Membranes were analyzed in a Li-Cor 
fluorescence reader (Li-Cor, Lincoln, NE).
Stimulation of OT1 CD8+ T cells
CD8+ T cells were purified from spleens of OT I 
mice (C57BL/6-Tg(TcraTcrb)1100Mjb/Crl, Charles River 
Labs) by negative selection with the CD8a+ mouse T 
cell isolation kit (Miltenyi Biotec). Separation efficiency 
was evaluated by FACS.  Purified CD8+ T cells (1 × 105 
cells/well) were co-cultured with BMDCs (5 × 104/well) 
stimulated as described above, in presence or absence of 
OVA peptide (25 µg/ml). Supernatants were collected after 
three days of co-culture for cytokine detection.
Statistical analysis
Statistical significance was evaluated using two-
tailed Student’s t test, comparing the mean ± SEM of 
at least 3 biological replicates per conditions. P-values 
< 0.05 were considered significant. Each experiment was 
repeated at least twice. Statistical analysis was done with 
GraphPad Prism 5 software (GraphPad Softwares Inc., 
CA).
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